Forest Labs - High Dose of Schizophrenia Drug Doesn't Meet Goal

(October 15, 2007) --

(Reuters) - Forest Laboratories Inc said high doses of its experimental antipsychotic drug did not show statistically significant improvement in a mid-stage trial for the treatment of schizophrenia.

However, low doses of the drug, RGH-188, showed a nominally statistically significant effect, Forest and Hungary's Gedeon Richter Plc said in a statement.

The companies said they plan to continue developing the drug as a treatment for schizophrenia. (Reporting by Esha Dey in Bangalore)

Source: Reuters

Last updated: 10/07

top ~ next ~ news table of contents ~ send page to a friend

We subscribe to the HONcode principles. Verify here.